UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________ Commission File Number: 001-38067 Verona Pharma plc (Exact name of Registrant as specified in its Charter) United Kingdom 98-1489389 (State or o ...

Developing innovative therapies for the treatment of respiratory diseases March 2022 Breath of Innovation™ Nasdaq: VRNA | www.veronapharma.com Forward-looking statements This presentation contains "forward‐looking" statements that are based on the beliefs and assumptions and on information currently available to management of Verona Pharma plc (together with its consolidated subsidiaries, the "Company"). All statements other than statements of historical fact contained in this presentation are forward-looki ...

Call Start: 09:00 January 1, 0000 9:33 AM ET Verona Pharma plc (NASDAQ:VRNA) Q4 2021 Earnings Conference Call March 3, 2022 09:00 ET Company Participants David Zaccardelli - President & Chief Executive Officer Mark Hahn - Chief Financial Officer Chris Martin - Senior Vice President of Commercial Kathleen Rickard - Chief Medical Officer Conference Call Participants Andreas Argyrides - Wedbush Securities Suji Jeong - Jefferies Tom Shrader - BTIG Operator Welcome to Verona Pharma's Fourth Quarter and Year End ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________ Commission File Number: 001-38067 Verona Pharma plc (Exact name of Registrant as specified in its Charter) Registrant's telephone number, including a ...

Verona Pharma plc (NASDAQ:VRNA) Q3 2021 Earnings Conference Call November 9, 2021 9:00 AM ET Company Participants David Zaccardelli - President and Chief Executive Officer Mark Hahn - Chief Financial Officer Kathy Rickard - Chief Medical Officer Conference Call Participants Andreas Argyrides - Wedbush Securities Boobalan Pachaiyappan - H.C. Wainwright Tom Shrader - BTIG Operator Welcome to Verona Pharma's Third Quarter 2021 Financial Results and Operating Highlights Conference Call. At this time, all partic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________ Commission File Number: 001-38067 Verona Pharma plc (Exact name of Registrant as specified in its Charter) United Kingdom 98-1489389 (State ...

Nasdaq: VRNA | www.veronapharma.com Developing innovative therapies for the treatment of respiratory diseases August 2021 Breath of Innovation™ Forward-looking statements This presentation contains "forward‐looking" statements that are based on the beliefs and assumptions and on information currently available to management of Verona Pharma plc (together with its consolidated subsidiaries, the "Company"). All statements other than statements of historical fact contained in this presentation are forward-look ...

Verona Pharma plc (NASDAQ:VRNA) Q2 2021 Earnings Conference Call August 5, 2021 8:30 AM ET Company Participants David Zaccardelli - President and CEO Mark Hahn - CFO Kathy Rickard - CMO Chris Martin - VP, Commercial Conference Call Participants Suji Jeong - Jefferies Sung Hong - BTIG Operator Welcome to Verona Pharma's Second Quarter 2021 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode. Earlier this morning, Verona Pharma issued a press re ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 United Kingdom 98-1489389 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM __________ TO __________ Commission File Num ...

Verona Pharma plc (NASDAQ:VRNA) Q1 2021 Earnings Conference Call April 29, 2021 9:00 AM ET Company Participants David Zaccardelli - President and CEO Mark W. Hahn - CFO Kathleen Rickard - CMO Christopher Martin - VP, Commercial Conference Call Participants Suji Jeong - Jefferies Liana Moussatos - Wedbush Securities Edward Nash - Canaccord Genuity Miguel Coelho - Truist Securities Operator Welcome to Verona Pharma's First Quarter 2021 Financial Results and Operating Highlights Conference Call. At this time, ...